Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients-Reference-Cited by-同舟云学术

Outcomes of relapsed/refractory diffuse large B‐cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line—A population‐based study of 736 patients

Published:2022-04-25 Issue:2 Volume:198 Page:267-277
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Harrysson Sara¹²^ORCID,Eloranta Sandra¹^ORCID,Ekberg Sara¹^ORCID,Enblad Gunilla³,El‐Galaly Tarec C.¹⁴,Sander Birgitta⁵^ORCID,Sonnevi Kristina²^ORCID,Andersson Per‐Ola⁶⁷^ORCID,Jerkeman Mats⁸,Smedby Karin E.¹²

Affiliation:

1. Division of Clinical Epidemiology Department of Medicine Solna Karolinska Institutet Stockholm Sweden

2. Department of Hematology Karolinska University Hospital Solna Sweden

3. Department of Immunology, Genetics and Pathology Uppsala University Uppsala Sweden

4. Department of Hematology Aalborg University Hospital Aalborg Denmark

5. Division of Pathology, Department of Laboratory Medicine Karolinska Institutet and Karolinska University Hospital Stockholm Sweden

6. Department of Hematology South Älvsborg Hospital Borås Sweden

7. Sahlgrenska Academy Gothenburg University Gothenburg Sweden

8. Department of Oncology Lund University Lund Sweden

Funder

Cancerfonden

Janssen Pharmaceuticals